Cogent Biosciences, Inc.
COGT
Rang în acțiuni
#3230
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Preț acțiune
$31.49
Ultima sincronizare: 2026-10-21
Capitalizare de piață
$5.46B
Schimbare (1 zi)
0.81%
Schimbare (1 an)
112.08%
Țară
US
Tranzacționează Cogent Biosciences, Inc. (COGT)
Categorie
Healthcare
Istoric al prețului acțiunii pentru Cogent Biosciences, Inc. (COGT)
Cel mai mare preț de închidere: $30.19 pe 2026-10-01
Cel mai mic preț de închidere: $44.44 pe 2018-03-01
Cel mai mic preț de închidere: $44.44 pe 2018-03-01
Istoric al prețului acțiunii pentru Cogent Biosciences, Inc. din 2018 până în 2026
Evoluția anuală a prețului acțiunii
| An | Performanță |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Prețul acțiunii pentru companii similare sau concurente
| Companie | Preț acțiune | Variație 1an% | Țara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $756.75 | 7.56% |
CH
|
